This summer, Health and Human Services Secretary Robert F. Kennedy, Jr. said he’d like to see psychedelic therapies for depression, trauma and other hard-to-treat disorders approved for use within the next 12 months. Last year the FDA rejected psychedelic-assisted therapy for use in treating PTSD. We check in with long-time researchers about how state and federal governments can influence the momentum of their field, how they’re reconciling the new right wing support, and what it all means for the future of psychedelic research and therapy.

Guests:

Michael Silver, director, UC Berkeley Center for the Science of Psychedelics

Marlena Robbins, Indigenous public health and policy consultant; doctor of public health candidate, UC Berkeley

Berra Yazar-Klosinski, founder and CEO, Yazar Lab, LLC; former chief scientific officer, Lykos Therapeutics

Learn more about your ad choices. Visit megaphone.fm/adchoices